Key result
Transesophageal atrial pacing terminates drug-refractory SVT in ~73% of neonates.
Why the study?
The therapeutic value of transesophageal atrial pacing for treating supraventricular tachycardia in newborns needed to be described and explored.
Does transesophageal atrial pacing (TEAP) terminate refractory supraventricular tachycardia in newborns?
Observational (n=22)
No
Does transesophageal atrial pacing (TEAP) terminate refractory supraventricular tachycardia in newborns?
Transesophageal atrial pacing is a safe and effective acute treatment for terminating refractory reentrant supraventricular tachycardia (AVRT and atrial flutter) in newborns, particularly those with heart failure.
Objective To describe and explore the therapeutic value of transesophageal atrial pacing (TEAP) for supraventricular tachycardia in newborns. Methods Clinical data from 22 cases (15 males, 7 females) at Shanghai Children's Hospital (2015–2025) were retrospectively analyzed to evaluate the efficacy of TEAP. Results Surface ECGs demonstrated paroxysmal SVT and type I atrial flutter in 11 cases respectively, with 8 patients having heart failure. After inserting the esophageal electrode catheter, transesophageal electrocardiography confirmed Atrioventricular Reentrant Tachycardia (AVRT) in 9 of 11 SVT cases; TEAP successfully terminated tachycardia in 7 (77.8% success). In a case, pulse stimulation had not yet been administered, a declining trend in blood pressure was observed, which necessitated electrical cardioversion. Another with short paroxysms post-TEAP was maintained on oral medication. Two cases of atrial tachycardia confirmed by transesophageal electrocardiogram did not respond to TEAP. Among 11 type I atrial flutter cases, TEAP restored sinus rhythm in 9 (81.8% success); one had intermittent short paroxysms and one showed reduced atrioventricular conduction, both switched to oral drugs. Conclusion TEAP is a relatively safe and effective acute treatment for reentrant SVT (AVRT, AFL) when medication cannot promptly and effectively terminate tachycardia, particularly for patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) conducted an observational in Supraventricular tachycardia (n=22). Transesophageal atrial pacing (TEAP) was evaluated on Acute termination of SVT (conversion to sinus rhythm) without early recurrence (within 24 h). Transesophageal atrial pacing successfully terminated drug-refractory supraventricular tachycardia in 77.8% of newborns with atrioventricular reentrant tachycardia and 81.8% with atrial flutter.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: